| 1 |
Vakil N, Van Zanten S, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus [J]. The American journal of gastroenterology, 2006, 101(8): 1900-1920; quiz 43.
|
| 2 |
屈坤鹏,成晓舟. 我国部分地区胃食管反流病患病率的 Meta 分析 [J]. 中华胃食管反流病电子杂志, 2015, 2(1):34-44.
|
| 3 |
Fock K, Talley N, Goh K, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barretts oesophagus [J]. Gut, 2016, 65(9): 1402-1415.
|
| 4 |
Hagymási K, Müllner K, Herszényi L, et al. Update on the pharmacogenomics of proton pump inhibitors [J]. Pharmacogenomics, 2011, 12(6): 873-88.
|
| 5 |
孙玮,何彩霞. CYP2C19基因型与奥美拉唑治疗消化道溃疡疗效的相关性 [J]. 中西医结合心血管病电子杂志, 2019, 22(7):198.
|
| 6 |
吕秋菊,蒲强红. CYP2C19基因多态性对质子泵抑制剂治疗胃食管反流病疗效影响的Meta分析 [J]. 基层医学论坛, 2016, 20(28):3918-3920.
|
| 7 |
Uno T, Niioka T, Hayakari M, et al. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations [J]. European journal of clinical pharmacology, 2007, 63(2): 143-149.
|
| 8 |
周陈西,刘孟娟. 奥美拉唑的合理应用 [J]. 中国药房,2011(8):762-763.
|
| 9 |
秦怡男. 质子泵抑制药治疗胃食管反流病患者的研究进展 [J]. 医疗装备, 2019(14): 186-187.
|
| 10 |
徐涛. 国内常见质子泵抑制剂的简单对比分析 [J]. 中国现代药物应用, 2015(12): 257-258.
|
| 11 |
鄢小华,林常誉,林文英. 质子泵抑制剂在治疗胃食管反流中的临床效果观察 [J]. 临床合理用药杂志, 2018(4):88-90.
|
| 12 |
Kinoshita Y, Ishimura N, Ishihara S. Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors? [J]. The American journal of gastroenterology, 2018, 113(10): 1417-1419.
|
| 13 |
Graham D, Dore M. Update on the Use of Vonoprazan: A Competitive Acid Blocker [J]. Gastroenterology, 2018, 154(3): 462-466.
|
| 14 |
Li W, Yang Y, Tian Y, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension [J]. International journal of pharmaceutics, 2011(408):157-162.
|
| 15 |
陆慧, 陈祥峰. 胃酸相关疾病治疗新药富马酸沃拉赞 [J]. 药学与临床研究, 2016, (5):395-398.
|
| 16 |
Xiao Y, Zhang S, Dai N, et al. Phase Ⅲ, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis [J]. Gut, 2020, 69(2): 224-230.
|
| 17 |
Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review [J]. Journal of gastroenterology and hepatology, 2019, 34(8): 1316-1328.
|
| 18 |
Miwa H, Igarashi A, Teng L, et al. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease [J]. Journal of gastroenterology, 2019, 54(8): 718-729.
|
| 19 |
Echizen H. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations [J]. Clinical pharmacokinetics, 2016, 55(4): 409-418.
|
| 20 |
黄群刚, 朱启华, 徐云根. 可逆型质子泵抑制剂新研究进 [J]. 药学进展, 2016(6):445-452.
|
| 21 |
马莉娜. 常用质子泵抑制剂的临床应用及不良反应 [J]. 养生保健指南, 2019(36):70.
|
| 22 |
中华医学会,中华医学会杂志社,中华医学会消化病学分会,等. 胃食管反流病基层诊疗指南(2019年) [J]. 中华全科医师杂志, 2019(7):635-641.
|
| 23 |
Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015 [J]. Journal of gastroenterology, 2016, 51(8): 751-767.
|
| 24 |
Kinoshita Y, Kato M, Fujishiro M, et al. Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study [J]. Journal of gastroenterology, 2018, 53(7): 834-844.
|
| 25 |
Johnson D, Katz P, Armstrong D, et al. The Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus [J]. Drugs, 2017, 77(5): 547-561.
|
| 26 |
Haastrup P, Thompson W, Søndergaard J, et al. Side Effects of Long-Term Proton Pump Inhibitor Use: A Review [J]. Basic & clinical pharmacology & toxicology, 2018, 123(2): 114-121.
|
| 27 |
冯军安. 不同疗程奥美拉唑治疗胃食管反流病的临床疗效比较 [J]. 中国民康医学, 2018(6):59-60.
|
| 28 |
苏德云. 胃食管反流病给予不同疗程奥美拉唑治疗的对比分析 [J]. 中外医疗, 2019(15):131-133.
|
| 29 |
徐晓军, 江雅峰. 奥美拉唑不同疗程治疗胃食管反流病的疗效观察 [J]. 中国药房, 2014(20):1870-1872.
|
| 30 |
吴雄健, 毛忠懿, 刘洪荣. 不同疗程的质子泵抑制剂对胃食管反流病的疗效分析 [J]. 中国医药科学, 2012(23):82+84.
|
| 31 |
Hsu P, Lu C, Wu D, et al. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis [J]. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 2015, 13(5): 859-866.
|